...
hcm-img

HUTCHMED DRC, Common Stock

HCM

NSQ

$15.105

-$0.47

(-3.02%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.74B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.29K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.75
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$11.93 L
$21.92 H
$15.105

About HUTCHMED DRC, Common Stock

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameHCMSectorS&P500
1-Week Return-8.68%-2.28%-0.57%
1-Month Return-8.57%-3.98%1.2%
3-Month Return-9.89%-9.71%7.56%
6-Month Return-16.42%-3.39%11.44%
1-Year Return-19.81%3.69%28.47%
3-Year Return-52.67%3.78%29.51%
5-Year Return-32.38%39.76%90.64%
10-Year Return16.27%106.88%203.73%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue204.89M227.98M356.13M426.41M838.00M[{"date":"2019-12-31","value":24.45,"profit":true},{"date":"2020-12-31","value":27.2,"profit":true},{"date":"2021-12-31","value":42.5,"profit":true},{"date":"2022-12-31","value":50.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue160.15M188.52M258.23M311.10M384.45M[{"date":"2019-12-31","value":41.66,"profit":true},{"date":"2020-12-31","value":49.04,"profit":true},{"date":"2021-12-31","value":67.17,"profit":true},{"date":"2022-12-31","value":80.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit44.74M39.46M97.89M115.31M453.55M[{"date":"2019-12-31","value":9.86,"profit":true},{"date":"2020-12-31","value":8.7,"profit":true},{"date":"2021-12-31","value":21.58,"profit":true},{"date":"2022-12-31","value":25.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin21.84%17.31%27.49%27.04%54.12%[{"date":"2019-12-31","value":40.34,"profit":true},{"date":"2020-12-31","value":31.98,"profit":true},{"date":"2021-12-31","value":50.79,"profit":true},{"date":"2022-12-31","value":49.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses189.76M236.13M426.21M523.00M436.23M[{"date":"2019-12-31","value":36.28,"profit":true},{"date":"2020-12-31","value":45.15,"profit":true},{"date":"2021-12-31","value":81.49,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.41,"profit":true}]
Operating Income(145.02M)(188.95M)(336.46M)(409.77M)18.38M[{"date":"2019-12-31","value":-789.22,"profit":false},{"date":"2020-12-31","value":-1028.28,"profit":false},{"date":"2021-12-31","value":-1831.06,"profit":false},{"date":"2022-12-31","value":-2230.04,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense7.83M9.38M114.06M6.22M75.32M[{"date":"2019-12-31","value":6.86,"profit":true},{"date":"2020-12-31","value":8.23,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":5.45,"profit":true},{"date":"2023-12-31","value":66.03,"profit":true}]
Pre-Tax Income(141.10M)(189.73M)(215.74M)(410.42M)58.31M[{"date":"2019-12-31","value":-242,"profit":false},{"date":"2020-12-31","value":-325.4,"profit":false},{"date":"2021-12-31","value":-370,"profit":false},{"date":"2022-12-31","value":-703.89,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income Taxes3.27M4.83M11.92M(283.00K)4.51M[{"date":"2019-12-31","value":27.47,"profit":true},{"date":"2020-12-31","value":40.52,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2.37,"profit":false},{"date":"2023-12-31","value":37.83,"profit":true}]
Income After Taxes(144.38M)(194.56M)(227.66M)(410.14M)53.80M[{"date":"2019-12-31","value":-268.37,"profit":false},{"date":"2020-12-31","value":-361.65,"profit":false},{"date":"2021-12-31","value":-423.16,"profit":false},{"date":"2022-12-31","value":-762.35,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(103.68M)(115.52M)(167.04M)(360.39M)101.09M[{"date":"2019-12-31","value":-102.56,"profit":false},{"date":"2020-12-31","value":-114.27,"profit":false},{"date":"2021-12-31","value":-165.23,"profit":false},{"date":"2022-12-31","value":-356.49,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(144.38M)(194.56M)(227.66M)(410.14M)100.78M[{"date":"2019-12-31","value":-143.26,"profit":false},{"date":"2020-12-31","value":-193.06,"profit":false},{"date":"2021-12-31","value":-225.9,"profit":false},{"date":"2022-12-31","value":-406.96,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
EPS (Diluted)(0.69)(0.96)(0.97)(2.68)0.97[{"date":"2019-12-31","value":-70.94,"profit":false},{"date":"2020-12-31","value":-98.68,"profit":false},{"date":"2021-12-31","value":-99.6,"profit":false},{"date":"2022-12-31","value":-276.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

HCM
Cash Ratio 2.15
Current Ratio 2.81
Quick Ratio 2.68

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HCM
ROA (LTM) -5.90%
ROE (LTM) -5.44%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HCM
Debt Ratio Lower is generally better. Negative is bad. 0.40
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.59

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HCM
Trailing PE NM
Forward PE 83.33
P/S (TTM) 4.48
P/B 3.60
Price/FCF NM
EV/R 4.65
EV/Ebitda 36.81
PEG NM

FAQs

What is HUTCHMED DRC share price today?

HUTCHMED DRC (HCM) share price today is $15.105

Can Indians buy HUTCHMED DRC shares?

Yes, Indians can buy shares of HUTCHMED DRC (HCM) on Vested. To buy HUTCHMED DRC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HCM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of HUTCHMED DRC be purchased?

Yes, you can purchase fractional shares of HUTCHMED DRC (HCM) via the Vested app. You can start investing in HUTCHMED DRC (HCM) with a minimum investment of $1.

How to invest in HUTCHMED DRC shares from India?

You can invest in shares of HUTCHMED DRC (HCM) via Vested in three simple steps:

  • Click on Sign Up or Invest in HCM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in HUTCHMED DRC shares
What is HUTCHMED DRC 52-week high and low stock price?

The 52-week high price of HUTCHMED DRC (HCM) is $21.92. The 52-week low price of HUTCHMED DRC (HCM) is $11.93.

What is HUTCHMED DRC price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of HUTCHMED DRC (HCM) is

What is HUTCHMED DRC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of HUTCHMED DRC (HCM) is 3.60

What is HUTCHMED DRC dividend yield?

The dividend yield of HUTCHMED DRC (HCM) is 0.00%

What is the Market Cap of HUTCHMED DRC?

The market capitalization of HUTCHMED DRC (HCM) is $2.74B

What is HUTCHMED DRC’s stock symbol?

The stock symbol (or ticker) of HUTCHMED DRC is HCM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top